Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina™. Ampio also received a notice of allowance of a similar patent from the Canadian Intellectual Property Office. These initial patents cover the North American territories and multiple additional patents for using Optina™ for the treatment of macular edema and diabetic retinopathy are pending worldwide.

According to Michael Macaluso, Ampio's CEO, "Optina™ is an ultra-low oral (capsule), not commercially available, dose of danazol for the treatment of DME. To our knowledge, no other oral drug to treat this condition exists and there is currently no drug approved by the FDA for this condition. The allowance of these patents in North America is an important step in the development and commercialization of this novel drug as they include multiple claims for the beneficial effects of ultra-low dose Optina™ on vascular hyperpermeability encountered in DME and other vascular leakage syndromes. These patents have an unusually long patent life that expires in 2030. In contrast, most drugs at this stage of development (just before a pivotal trial) have exhausted a large portion of their patent life. These patent claims provide especially strong protection because of the unexpected finding of efficacy only at the very low doses. Ampio is currently in discussions with potential partners to co-develop Optina™ for DME."

Dr. David Bar-Or, Chief Scientific Officer for Ampio, explained, "The mode of action of Optin
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  Northstar Global Business Services, Inc. ... (DTC) has made their final decision and has ... Company,s stock effective December 15, 2014, and has ... depository and book entry transfer services. All deposit restrictions ... once again fully "DTC Eligible", and has resumed ...
(Date:12/17/2014)... 17, 2014 , ... a hub of information concerning the biopharmaceutical Group,s national and ... further addition to the recently launched institutional website that is ... been enriched by a new chapter in the fascinating story ... richly detailed and panoramic hub on the world of clinical ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... the 78th Annual American Society of Plastic Surgeons ... study that confirms that VASER-Assisted Lipoplasty (VAL) delivers ... skin retraction and blood loss. , In ... Controlled Clinical Trial Comparing VASER-Assisted Lipoplasty and Suction-Assisted ...
... , WAYNE, Pa., Oct. 23 Escalon Medical Corp. ... Digital Solutions subsidiary released its Web-Based AXIS(TM) Image Management ... diagnostic images from different sources into a single searchable ... trends over time across multiple imaging modalities, and improve ...
Cached Medicine Technology:New Study Confirms VASER Lipo Results Are Superior to Standard Liposuction 2Escalon(R) Subsidiary Escalon Digital Solutions Announces Release of Web-Based AXIS(TM) Image Management System 2Escalon(R) Subsidiary Escalon Digital Solutions Announces Release of Web-Based AXIS(TM) Image Management System 3
(Date:12/21/2014)... 21, 2014 Theme and ... new intro plugin for Final Cut Pro X entitled ... logos, and more with absolute ease.” Said Christiana Austin, ... the tools needed to easily animate their media inside ... Pro X users to animate pictures, videos, logos, and ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering many kinds ... shown its new engineered bamboo flooring collection, and announced ... , BambooIndustry.com’s customers come from many countries in the ... the CEO of the company, the global bamboo flooring ... few years, and the demand for eco-friendly bamboo flooring ...
(Date:12/20/2014)... company LunaDress has recently announced its 2015 collection ... discounts on all of its special occasion dresses & wedding ... perfect wedding gown. If you have no idea of what ... Many different wedding dress styles and our dress experts are ... the current special offer, up to 80% off," the CEO ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The Doctor’s Office ... for the better part of a decade. They’ve treated ... a better, faster healthcare alternative to the Paramus ... announce three new additions to their staff of top-notch board ... Jill Zeiger MD. These new doctors will work ...
(Date:12/20/2014)... 2014 Recently, AngelWeddingDress.com has introduced its ... for the coming Christmas. In the promotion, all buyers ... , “We have something special for the women who ... season. Moreover, our new collections of 2015 dresses have ... now at greatly discounted prices. Visit our website now ...
Breaking Medicine News(10 mins):Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... Reporter , TUESDAY, June 28 (HealthDay News) -- Mammography screening ... long believed, according to a new, large-scale Swedish trial. ... -- the longest ever -- the researchers found that the ... on. In fact, most of the benefits occur more ...
... used by thousands of people every day, are a ... 187,000 Americans visited the hospital after sustaining stepladder injuries, ... human factors/ergonomics study explores how improved design and user ... In their upcoming HFES 55th Annual Meeting presentation, ...
... A longtime dean of the University of Houston,s College ... group of optometrists as the first UHCO-affiliated person to be ... William R. Baldwin, O.D., who was the UHCO dean from ... Caplan, O.D., and Gerald E. Lowther, O.D. during the ...
... (HealthDay News) -- ,A new study hints at one reason that ... disease than whites: Blacks appear to have higher levels of a ... not detected in standard screening. This so-called "non-calcified plaque" -- ... of arteries -- can rupture and send out blood clots that ...
... with social interaction and attentiveness, and are also sensitive ... evident to parents during their child,s first two years, ... of Gothenburg. In her thesis, Dewrang investigated ... relative to their diagnosis. The thesis is based on ...
... Egocentric, self-centred, and insensitive to the needs of others: ... traumatic brain injury (TBI) and have been attributed in ... to recognise and understand the emotions of other people. ... and resulting empathy deficits can have negative repercussions on ...
Cached Medicine News:Health News:Longest Trial Ever Confirms Mammograms' Benefits 2Health News:Longest Trial Ever Confirms Mammograms' Benefits 3Health News:Improved stepladder design may decrease injuries 2Health News:Former dean first from UH to be inducted into Optometry Hall of Fame 2Health News:Study Hints at Why Heart Disease Is More Deadly for Blacks 2Health News:Lack of empathy following traumatic brain injury linked to reduced responsiveness to anger 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: